NMT Arbitration Ends With Sale Of Disputed Vena Cava Assets To Bard
This article was originally published in The Gray Sheet
Executive Summary
Expanded commercialization of NMT Medical's CardioSeal cardiac septal occluder system will be funded in part by the recent sale of the firm's vena cava filter business to C.R. Bard for up to $34 mil. plus royalties.
You may also be interested in...
Retrievable Vena Cava Filter Claim Sought By Cook; Bard First To U.S. Market
Cook, Inc. is seeking 510(k) clearance for removable use of its Günther Tulip MReye vena cava filter
Retrievable Vena Cava Filter Claim Sought By Cook; Bard First To U.S. Market
Cook, Inc. is seeking 510(k) clearance for removable use of its Günther Tulip MReye vena cava filter
FDA Taps Neurologists For NMT Medical’s PFO Closure Device, First To Panel
NMT Medical's PMA filing for its StarFlex implant for the closure of patent foramen ovale will be the first device to be reviewed for that indication by FDA's Circulatory System Devices Panel, the company notes